Associate Professor of Medicine, University Tex Houston
Hematology
Dr. Luis E. Fayad, MD
|
|
Give Review
Luis Fayad practices Hematology. He received 1 awards: "Regional Top Doctor". Doctor Luis E. Fayad, MD is also published. He has 57 publications published. The lastest publication: "Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Ea...' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Ea...
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung Cancer.
- Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin Lymphoma.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-Cell lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma.
- Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis -TAFRO Syndrome.
- Detection of classical Hodgkin Lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-Cell lymphoma relapsing after rituximab, cycloph...
- Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone...
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B Cell lymphoma? - Response to Lan...
- Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin...
- Classical hodgkin Lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
- Recent advances in de novo CD5(+) Diffuse Large B Cell Lymphoma (DLBCL).
- Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-Cell lymphoma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-Cell lymphoma.
- Non-Hodgkin's Lymphomas, Version 1.2013.
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II...
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for Lymphomas: a prospective, randomized controlled phase III trial.
- Verapamil synergistically enhances cytotoxicity of bortezomib in mantle Cell lymphoma via induction of reactive oxygen species production.
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/R...
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis Syndrome.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed Lymphoma.
- B-Cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-Cell immunophenotyp...
- Prognostic value of MYC rearrangement in cases of B-Cell lymphoma, unclassifiable, with features intermediate between diffuse large B-Cell lymphoma and Burkitt lymphoma.
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle Cell lymphoma.
- Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin Lymphoma: phase 1 stud...
- Non-Hodgkin's Lymphomas.
- Marginal zone Lymphomas: factors that affect the final outcome.
- Beyond R-CHOP and the IPI in large-Cell lymphoma: molecular markers as an opportunity for stratification.
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal ly...
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle Cell lymphoma.
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin Lymphoma.
- Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's Lymphoma: results from a phase II multicenter, single-agent study.
- Follicular dendritic Cell sarcoma: a report of 14 cases and a review of the literature.
- K1 protein of human herpesvirus 8 suppresses lymphoma Cell Fas-mediated apoptosis.
- Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin Lymphoma.
- Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B Cell...
- Stage III follicular Lymphoma: long-term follow-up and patterns of failure.
- Frequency of gastrointestinal involvement and its clinical significance in mantle Cell lymphoma.
- Radiotherapy alone for lymphocyte-predominant Hodgkin's Disease.
- Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma.
Schools
Universidad Catolica De Santiago De Guayaquil Facultad De Medicina
Jackson Meml Hospital University Miami School Med
University Tx MD Anderson Cancer Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Texas Health Science Center -
Jackson Memorial Hospital - Jackson Health System -
Universidad Catolica de Santiago de Guayaquil
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1205921095 | |
| NPPES Provider LastName | FAYAD | |
| NPPES Provider FirstName | LUIS | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 275.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205921095 |
| Last Name Of The Provider | FAYAD |
| First Name Of The Provider | LUIS |
| View All |
Similar Doctors
|
|
Dr. Vilmos A. Thomazy, MD |
|
|
Dr. Merrill S. Kies, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jason Westin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tri T. Vu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent Valero, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jorge R. Quesada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna Przepiorka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward S. Kim, MD |
|
|
Dr. Amy A. Hassan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl F. Hirsch-Ginsberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hun J. Lee, MD |
|
|
Dr. Bryan K. Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Cyprus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad Pecot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ana Aparicio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mohamed Haq, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed K. Azeemuddin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ibrahim F. Ibrahim, MD |
|
|
Dr. Xiaohong I. Wang, MD |
|
|
Betty J. Springfield |